RxDoctor Payments Data

Bryan Reed

Psychiatric/Mental Health · Greensburg, PANPI 1811626187

Payments from drug & device makers

$4,950in general payments, 2019–2025

Across 223 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$690
  • Alkermes, Inc.$506
  • Otsuka America Pharmaceutical, Inc.$444
  • Lundbeck LLC$433
  • Neurocrine Biosciences, Inc.$412
  • plus $1K from 8 others

What the payments were for

  • Food & beverage$4,83998%
  • Education$1112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,950 in reported general payments places this provider in the 90th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$8,795
Medicare patients
22
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl26$121,150
RexultiBrexpiprazole12$16,322
VraylarCariprazine Hcl11$14,248
Aripiprazole77$2,667
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine27$2,606
Lurasidone Hcl12$1,959
Bupropion XlBupropion Hcl89$1,882
Mirtazapine132$1,476
Trazodone Hcl163$1,379
Buspirone Hcl94$1,296
Sertraline Hcl154$1,210
Duloxetine Hcl85$1,197
Venlafaxine Hcl ErVenlafaxine Hcl67$1,187
Doxepin Hcl24$1,138
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine45$1,026

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$366$121,15026 claims
Otsuka America Pharmaceutical, Inc.Rexulti$444$16,32212 claims
AbbVieVraylar$1,462$14,24811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Greensburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →